Date: 2012-11-07
Type of information: Services contract
Compound: microarrays
Company: Agilent Technologies (USA) Roche (Switzerland)
Therapeutic area:
Type agreement: services
Action mechanism:
Disease:
Details: Agilent Technologies and Roche announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases out its NimbleGen array production and services. Researchers using NimbleGen microarrays for all applications, including comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation and gene expression can transition to Agilent arrays, effective immediately, with minimal disruption. The similarities of the technologies and products from both companies provide an optimal transition path and the ability to run Agilent microarrays on the NimbleGen MS 200 Microarray Scanner.
Financial terms:
Latest news:
